Related Articles Pharmaceutical Business Review

Posted by e_kofman in What Is It on October 8, 2009 at 7:03 am

Related Articles Pharmaceutical Business Review

UCB has reported its interim report for the first nine months of 2009. As expected, revenue declined in the first nine months of 2009 compared to the same period in 2008 as a consequence of generic competition to Keppra in the US. This was partially compensated by the strong performance of Keppra in Europe which continued to show double-digit percentage net sales growth and by ...Technorati search for Levetiracetam has no resultsMylan Inc. today announced its financial results for the three and nine months ended September 30, 2009.Research and Markets has announced the addition of the "Commercial Insight: Anticonvulsants - Non-epilepsy Label Expansions Provide Blockbuster Potential" report to their offering.DUBLIN----Research and Markets has announced the addition of the "Commercial Insight: Anticonvulsants - Non-epilepsy Label Expansions Provide Blockbuster Potential" report to their offering.Pharmalink AB announced today that it has been granted Japanese Patent No 4326696, "Methods and means for treating glomerulonephritis" for its product Nefecon which is being developed to treat IgA nephropathy, a glomerulonephritis leading to end-stage renal disease . Counterparts of the patent have been issued for other territories including the EU, US and China.
 
Comment   Permalink    Please Share:  email this  +SU


Interim Report Promising early results for UCBs new products Marketwire via Yahoo Finance

Posted by jinseok in What Is It on October 8, 2009 at 7:03 am

BRUSSELS, BELGIUM-- - * Financial performance in line with expectations * Strong early roll-out of major new products Cimzia, Vimpat and Neupro * Diversification of debt begun with successful offering of EUR 500 million convertible bonds * Financial outlook 2009 confirmed Brussels , October 22, 2009 - 07:00 - regulated information - UCB announced today its ...BRUSSELS, BELGIUM-- - * Financial performance in line with expectations * Strong early roll-out of major new products Cimzia®, Vimpat® and Neupro® * Diversification of debt begun with successful offering of EUR 500 million convertible bonds * Financial outlook 2009 confirmed Brussels , October 22, 2009 - 07:00 - regulated information - UCB announced ...
 
Comment   Permalink    Please Share:  email this  +SU


COMMENT

1 comments to "Cat Pizza"

  1. kurdahi
    October 3th, 2009 at 04:20PM

    kurdahi say: what !! :O
    O.M.G. he is so sick!
    I like you man XD
    But pleas, don't sing ;/
    ( I'm sorry for my English ^_^ )


PLEASE LEAVE A COMMENT

Neatorama Comment Policy
You don't have to register or login to comment, but it's easier if you do so. Comments aren't censored, but those that are abusive or off-topic may be edited or deleted.


See the rest of Neatorama: